A significant proportion of individuals diagnosed with Type 2 diabetes, exceeding one in four, currently utilize glucagon-like peptide-1 (GLP-1) receptor agonists, a prominent class of pharmaceutical interventions. However, novel investigations spearheaded by researchers at Stanford Medicine, in collaboration with an international consortium of scientists, posit that inherent genetic predispositions may substantially influence the therapeutic effectiveness of these medications for a subset of patients.
Approximately ten percent of the global population harbors specific genetic markers that have been correlated with a recently identified physiological phenomenon termed GLP-1 resistance. In these individuals, the endogenous levels of GLP-1, a crucial hormone instrumental in blood glucose regulation, are paradoxically elevated yet demonstrate diminished functional capacity. This observation challenges the conventional understanding of how this hormone operates and suggests a more intricate regulatory network at play.
The implications of these genetic variations for weight loss outcomes, particularly in the context of medications like Ozempic and Wegovy, which are increasingly prescribed off-label for obesity treatment at higher dosages than for diabetes, remain an area of ongoing inquiry. While these drugs are designed to harness the metabolic benefits of GLP-1, their impact on weight reduction may be modulated by an individual’s genetic makeup.
This comprehensive study, the findings of which were published on March 29 in the esteemed journal Genome Medicine, meticulously examined the impact of these genetic factors on blood sugar regulation. The research effort represents a culmination of a decade of dedicated scientific endeavor, encompassing experimental work conducted on both human subjects and murine models, alongside an in-depth analysis of extensive clinical trial data.
Dr. Anna Gloyn, a distinguished professor of pediatrics and genetics at Stanford Medicine and one of the study’s senior authors, remarked on the findings from clinical trials. She noted that "in some of the trials, we observed that individuals carrying these specific genetic variants exhibited a reduced capacity to lower their blood glucose levels effectively following a six-month treatment period." This observation has direct clinical relevance, as it suggests that physicians, armed with such genetic information, could potentially tailor treatment regimens more precisely, thereby accelerating the process of identifying the most efficacious medications for each patient. This represents a significant stride towards the realization of precision medicine, where therapeutic interventions are customized based on an individual’s unique biological profile.
The study’s other senior author is Dr. Markus Stoffel, a professor of metabolic diseases at the Institute of Molecular Health Sciences at ETH Zurich in Switzerland, a globally recognized center for biomedical research. The lead authorship of this groundbreaking work was shared by Dr. Mahesh Umapathysivam, an endocrinologist and clinical researcher affiliated with Adelaide University in Australia, who was a former trainee under Dr. Gloyn’s mentorship, and Dr. Elisa Araldi, an associate professor of medicine and surgery at the University of Parma in Italy, who previously trained with Dr. Stoffel.
Dr. Umapathysivam, drawing from his clinical experience in diabetes management, highlighted the persistent challenge of predicting patient responses to GLP-1-based medications. He stated, "When I treat patients in the diabetes clinic, I observe a considerable heterogeneity in response to these GLP-1-based medications, and clinically predicting this response is difficult." He further emphasized the significance of this research, asserting, "This marks the initial phase in our ability to leverage an individual’s genetic constitution to refine clinical decision-making processes."
Despite this being the most thorough investigation to date into the intricacies of GLP-1 resistance, the precise underlying biological mechanisms continue to elude complete elucidation.
"That remains the pivotal question, the million-dollar puzzle," Dr. Gloyn acknowledged. "We have systematically investigated and systematically ruled out a comprehensive array of proposed mechanisms by which GLP-1 resistance might manifest. Despite our rigorous efforts, we have not yet definitively pinpointed the exact reason for this resistance."
The research specifically zeroed in on two distinct genetic variants that exert an influence on the activity of an enzyme known as peptidyl-glycine alpha-amidating monooxygenase (PAM). This enzyme plays a singularly critical role in the post-translational modification and subsequent activation of a multitude of peptide hormones within the body, including GLP-1.
"PAM is a truly remarkable enzyme, not only for its unique catalytic capability but also for its essential role in amidation, a chemical process that significantly enhances the stability and potency of biologically active peptides," Dr. Gloyn explained. "Our initial hypothesis was that if there were any functional impairments in this enzyme, it would likely lead to dysregulation across various biological systems."
Prior research had already established a correlation between certain PAM variants and an increased prevalence of diabetes, along with potential disruptions in insulin secretion from the pancreas. The current research team aimed to ascertain whether these variants also adversely affected the function of GLP-1, a gut-derived hormone that plays a vital role in postprandial glucose homeostasis by stimulating insulin release, retarding gastric emptying, and suppressing appetite. The GLP-1 receptor agonist drugs are engineered to emulate the physiological actions of this hormone.
To rigorously explore this hypothesis, the researchers recruited adult participants, both with and without a specific PAM variant designated as p.S539W. These individuals underwent a standardized oral glucose tolerance test, involving the ingestion of a sugary solution, with subsequent blood sampling at five-minute intervals over a four-hour duration. The study deliberately excluded individuals with diabetes to minimize potential confounding factors that could obscure the genetic influence on GLP-1 signaling.
The prevailing expectation among the researchers was that individuals possessing the PAM variant would exhibit diminished circulating levels of GLP-1, possibly due to a compromised stability of the hormone resulting from impaired enzymatic processing.
"To our surprise, the data revealed the opposite: we observed elevated levels of GLP-1 in these individuals," Dr. Gloyn stated. "This finding was contrary to our initial predictions."
She further elaborated, "Despite the presence of higher circulating GLP-1 concentrations in individuals with the PAM variant, we found no evidence of enhanced biological activity. Their blood sugar levels did not decrease more rapidly, indicating that a greater quantity of GLP-1 was required to elicit the same physiological response, a clear indication of GLP-1 resistance."
Given the unexpected nature of these initial findings, the research team embarked on a multi-year endeavor to rigorously validate their observations through a variety of complementary experimental approaches.
"The unexpectedness of the results compelled us to seek confirmation through as many diverse methodologies as possible to ascertain the robustness of our observations," Dr. Gloyn emphasized.
This validation process involved a collaborative effort with scientists in Zurich who were investigating genetically modified mice lacking the functional PAM gene. These murine models exhibited a striking parallel to the human findings, demonstrating elevated GLP-1 levels coupled with an impaired ability to regulate blood glucose effectively.
One of the critical physiological roles of GLP-1 is to decelerate the rate at which food moves through the stomach, a process that contributes significantly to blood sugar stabilization and plays a role in satiety and weight management. In the PAM-deficient mice, gastric emptying was accelerated, and exogenous administration of GLP-1 analogs failed to restore this regulatory function.
Furthermore, the researchers detected a reduced responsiveness to GLP-1 in key tissues such as the pancreas and the gastrointestinal tract of these mice. Notably, the density of GLP-1 receptors in these tissues remained unchanged, suggesting that the locus of resistance was not at the receptor binding site.
Subsequent investigations, conducted in collaboration with researchers in Copenhagen, indicated that the PAM genetic defect did not interfere with the binding affinity of GLP-1 to its receptor or the subsequent intracellular signaling cascades. This finding points towards a disruption occurring downstream in the GLP-1 signaling pathway.
To assess the clinical ramifications of GLP-1 resistance, the research team meticulously analyzed data derived from several large-scale clinical trials involving individuals diagnosed with diabetes.
A pooled analysis encompassing data from three distinct trials, comprising a total of 1,119 participants, revealed that individuals carrying PAM variants exhibited a demonstrably poorer response to GLP-1 receptor agonist medications. These individuals were significantly less likely to achieve target HbA1c levels, a key clinical marker of long-term glycemic control. Specifically, after six months of treatment, approximately 25% of participants without the genetic variants attained their recommended HbA1c target, contrasting sharply with the 11.5% and 18.5% observed in those carrying the p.S539W and p.D563G variants, respectively.
Crucially, these identified genetic variants did not appear to influence patient responses to other widely prescribed classes of diabetes medications, including sulfonylureas, metformin, and dipeptidyl peptidase-4 inhibitors (DPP-4is).
"The most striking observation was the absence of any discernible impact of these variants on the response to other therapeutic agents for diabetes," Dr. Gloyn commented. "This strongly indicates that the observed resistance is specific to medications that exert their effects through the GLP-1 receptor signaling pathway."
Two additional clinical trials, funded by pharmaceutical entities, failed to demonstrate a significant difference in response between carriers and non-carriers of the PAM variants. However, these studies utilized longer-acting formulations of GLP-1 drugs, which, according to Dr. Gloyn, may possess the capacity to mitigate or overcome GLP-1 resistance.
The underlying biological basis for GLP-1 resistance remains a complex and as yet unresolved scientific enigma. Researchers first began to observe indications of GLP-1 resistance approximately a decade ago, predating the widespread adoption of GLP-1 drugs for weight management. While only two of the analyzed trials included data pertaining to weight loss, these datasets did not reveal a definitive or consistent difference between individuals with and without the identified PAM variants, suggesting that the data is currently insufficient to draw firm conclusions.
It is highly probable that additional genetic data, potentially residing within the archives of numerous clinical trials, could offer further insights into the varied responses observed with these medications. However, accessing and analyzing such data presents significant logistical and ethical challenges.
"It is a common practice for pharmaceutical companies to collect genetic information from participants in their clinical trials," Dr. Gloyn noted. "For the newer generation of GLP-1 medications, it would be immensely beneficial to investigate whether genetic variants, such as those identified in the PAM gene, can account for the suboptimal responses observed in certain patient populations."
At present, the precise molecular mechanisms driving GLP-1 resistance are not fully understood and are likely influenced by a confluence of multiple biological factors. Dr. Gloyn drew an analogy to insulin resistance, a condition that has been the subject of extensive research for decades yet still presents complexities that are not entirely comprehended. Despite this lack of complete understanding, effective therapeutic strategies for managing insulin resistance have been successfully developed.
"There exists an entire class of medications that enhance insulin sensitivity; therefore, it is conceivable that we could develop analogous therapies that render individuals more sensitive to GLP-1 agonists, or identify novel formulations of GLP-1, such as the extended-release versions, that effectively circumvent the phenomenon of GLP-1 resistance," she concluded.
The collaborative research effort involved contributions from esteemed institutions including the University of Oxford, the University of Dundee, the University of Copenhagen, the University of British Columbia, Churchill Hospital, Newcastle University, the University of Bath, and the University of Exeter.
This pioneering study received financial support from a diverse range of funding bodies, including Wellcome, the Medical Research Council, the European Union Horizon 2020 Programme, the National Institutes of Health (grants U01-DK105535, U01-DK085545, and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim, and Diabetes Australia.
About the Author
